pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,347 catalysts · 18,987 approval · 5,347 phase readout · 5,000 device 510k · 4,728 grant · 2,603 8k filing · 2,000 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 0 catalysts2026-07-31: 0 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 17 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 2 catalysts2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
hide past →
sort
soonestlatesttypesponsoralpha
type: phase readout×clear all
type
  • approval18,987
  • phase readout5,347
  • device 510k5,000
  • grant4,728
  • 8k filing2,603
  • device pma2,000
  • device recall
2,000
  • recall1,126
  • device adverse event1,000
  • pdufa347
  • therapy area

    no tagged catalysts yet

    Date TBD

    50
    ›COMPLETEDphase readoutNCT07236268: Prevalence of HIV and Sexually Transmitted Infections in Migrant Communities in Slovakia

    Sponsor: Comenius University. Phase: . Conditions: STIs, HIV, Rapid Detection

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05621850: Impact of CErebral Endovascular PROcedures on the Systemic Immune responSe Response

    Sponsor: University Hospital, Limoges. Phase: NA. Conditions: Cerebral Arterio-venous Malformation

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07571291: DEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSIS

    Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia. Phase: . Conditions: Pulmonary Fibrosis

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06094491: Virtual Diabetes Group Visits Across Health Systems

    Sponsor: University of Chicago. Phase: NA. Conditions: T2DM (Type 2 Diabetes Mellitus), Hypertension, Heart Disease Chronic, Stroke, Hyperlipidemias, Peripheral Vascular Diseases, Obesity

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07260760: Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke

    Sponsor: Qianfoshan Hospital. Phase: . Conditions: Acute Ischemic Stroke

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07493460: Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

    Sponsor: Washington University School of Medicine. Phase: PHASE4. Conditions: Immunology, Healthy Adults

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04273360: Restrictive Use of Restraints and Delirium Duration in ICU

    Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: NA. Conditions: Restraint, Physical, Mechanical Ventilation

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07414160: Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients

    Sponsor: The First Hospital of Jilin University. Phase: . Conditions: ICU, Critical Illness, Adult

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07588360: Haplo-Cord HSCT for AML/MDS

    Sponsor: Fujian Medical University Union Hospital. Phase: NA. Conditions: MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05304715: Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

    Sponsor: Hellenic Institute for the Study of Sepsis. Phase: PHASE2. Conditions: Clostridioides Difficile Infection, Stool Microbiome, Organ Dysfunction Syndrome, Clostridioides Difficile Infection Recurrence, Mortality

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07363915: Group Program vs Single-Session Depathologizing Intervention for Subthreshold Anxiety-Depression in Primary Care (Spain)

    Sponsor: University of Alcala. Phase: NA. Conditions: Anxiety, Depressive Symptoms, Anxiety Symptoms, Subthreshold Depression

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06453525: PrediSuisse: Automatized Assessment of Difficult Airway

    Sponsor: Centre Hospitalier Universitaire Vaudois. Phase: . Conditions: Anesthesia, Intubation; Difficult or Failed, Airway Complication of Anesthesia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05036226: COAST Therapy in Advanced Solid Tumors and Prostate Cancer

    Sponsor: Medical University of South Carolina. Phase: PHASE1. Conditions: Prostate Cancer Recurrent, Solid Tumor, Adult

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03965689: Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

    Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07661368: Cooking Health-Oriented Meals to Prevent Dementia and Diabetes

    Sponsor: Virginia Polytechnic Institute and State University. Phase: NA. Conditions: Type 2 Diabetes, Dementia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07227168: A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    Sponsor: Sutro Biopharma, Inc.. Phase: PHASE1. Conditions: Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05983068: A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

    Sponsor: Sanofi. Phase: PHASE4. Conditions: Dermatitis Atopic

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03531450: Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients

    Sponsor: Massachusetts General Hospital. Phase: NA. Conditions: Gastroparesis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01833650: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer

    Sponsor: Cyprus University of Technology. Phase: NA. Conditions: Thyroid Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05022550: Virtual-reality and Emotion Regulation in Violence-Exposed Youth

    Sponsor: University of Wisconsin, Madison. Phase: NA. Conditions: Emotional Regulation, Adolescent Behavior

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05845450: Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

    Sponsor: Gruppo Oncologico del Nord-Ovest. Phase: PHASE2. Conditions: Colorectal Cancer, Resectable Colorectal Carcinoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07346391: Augmentation of Peri-implant Keratinized Mucosa Using a Combination of Free Gingival Graft Strip With Platelet-Rich Fibrin

    Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City. Phase: NA. Conditions: Dental Implants

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06902974: Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

    Sponsor: Sunstone Medical. Phase: PHASE2. Conditions: Post Traumatic Stress Disorder, PTSD

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04991974: Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine

    Sponsor: Friends Research Institute, Inc.. Phase: PHASE2. Conditions: Opioid-use Disorder

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07203274: The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch

    Sponsor: Aalborg University. Phase: NA. Conditions: Itchiness

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT00081874: RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Leukemia, Mantle Cell Lymphoma, Myelofibrosis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07452874: Community-Based Occupational Therapy for Syrian Refugees to Improve Social Participation and Occupational Justice

    Sponsor: Kocaeli University. Phase: NA. Conditions: Refugees, Occupational Injustice

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07532018: DXP-106 in Solid Tumor Patients.

    Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd.. Phase: PHASE1. Conditions: Solid Tumor, Cancer

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07695818: Testing and Evaluation of the Returning to the Land Intervention to Address and Prevent Substance Misuse

    Sponsor: Johns Hopkins Bloomberg School of Public Health. Phase: NA. Conditions: Substance Use, Children, Cultural Factors

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05766813: Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

    Sponsor: Intra-Cellular Therapies, Inc.. Phase: PHASE2. Conditions: Parkinson Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07092813: Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents

    Sponsor: Iterum Therapeutics, International Limited. Phase: PHASE1. Conditions: Pharmacokinetics After Oral Intake

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05760313: A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

    Sponsor: AbbVie. Phase: PHASE2. Conditions: Functional Constipation

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06740110: Bone Material's Histomorphometric Analysis In Socket Preservation

    Sponsor: Medical Inventi S.A.. Phase: NA. Conditions: Socket Preservation

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02838420: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

    Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04433520: Trevisio Post-Approval Study

    Sponsor: Abbott Medical Devices. Phase: . Conditions: PFO - Patent Foramen Ovale, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PIVSD - Post Infarct Muscular Ventricular Septal Defect

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07366320: Effects of Four-Week Rhodiola Rosea Supplementation on Physical Fitness, Neuromuscular Performance, and Decision-Making in Competitive Football Players

    Sponsor: Beijing Sport University. Phase: NA. Conditions: Physical Performance and Fatigue in Competitive Football Players

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02220920: Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

    Sponsor: Tanabe Pharma Corporation. Phase: PHASE4. Conditions: Type 2 Diabetes Mellitus

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05552820: Electroacupuncture for Mild-to-moderate Dry Eye

    Sponsor: Shanghai Institute of Acupuncture, Moxibustion and Meridian. Phase: NA. Conditions: Dry Eye

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06821282: Surveillance of AMR in DRC

    Sponsor: University of Oxford. Phase: . Conditions: Bacteremia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06315582: Surgical Approach to Uterine Septum

    Sponsor: Northwestern University. Phase: NA. Conditions: Uterine Septum, Surgical Complication, Septum; Uterus, Treatment Side Effects, Treatment

    full page →ctgov ↗
    ›AVAILABLEphase readoutNCT06751524: Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

    Sponsor: Agenus Inc.. Phase: . Conditions: Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), Melanoma, Sarcoma, Ovarian Cancer, Prostate Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07480824: To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

    Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Phase: PHASE1. Conditions: Myelofibrosis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07467824: Impact of Prehabilitation and Comprehensive Follow-up in Women With Breast Cancer

    Sponsor: European University Miguel de Cervantes. Phase: NA. Conditions: Breast Cancer, Breast Neoplasms

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07352124: Rosemary Infusion for Hypertension With Hypertriglyceridemia

    Sponsor: awatef Sassi. Phase: NA. Conditions: Hypertension With Hypertriglyceridemia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06637423: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

    Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE1. Conditions: Non-Muscle Invasive Bladder Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07400523: Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

    Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Phase: PHASE3. Conditions: Breast Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06776523: Boosting Refugee Integration Through Psychological Intervention

    Sponsor: University of Zurich. Phase: NA. Conditions: Psychological Distress, PTSD, Trauma, Common Mental Health Problems

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05411523: Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy

    Sponsor: Mayo Clinic. Phase: . Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05610059: Improving Hypertension Medication Adherence for Older Adults

    Sponsor: University of Arizona. Phase: NA. Conditions: Aging, Medication Adherence, Hypertension

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07580859: Antenatal vs Postnatal Transport Team Positioning in Extremely Preterm Outborn Infants

    Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: . Conditions: Prematurity Complications, Neurodevelopment Outcome, Prematurity

    full page →ctgov ↗
    ← prev
    page 104 of 107
    next →